Sinovac Biotech Operating Cash Flow Growth & History (SVA)

Sinovac Biotech's operating cash flow was −$512.2M for fiscal 2025.

View full Sinovac Biotech company overview

Sinovac Biotech annual operating cash flow history

Sinovac Biotech annual operating cash flow

Fiscal yearPeriod endedOperating cash flowChangeGrowth
20252025-12-31−$512.2M−$455.3M
20242024-12-31−$56.9M−$195.5M
20232023-12-31$138.6M$936.8M
20222022-12-31−$798.1M−$16.12B
20212021-12-31$15.32B$14.84B+3096.67%
20202020-12-31$479.3M$440.2M+1126.67%
20192019-12-31$39.1M$31.1M+391.93%
20182018-12-31$7.9M−$51.8M−86.71%
20172017-12-31$59.8M$73.7M
20162016-12-31−$13.9M−$18.1M
20152015-12-31$4.2M$14.3M
20142014-12-31−$10.1M−$15.7M
20132013-12-31$5.6M$21.8M
20122012-12-31−$16.3M−$30.2M
20112011-12-31$13.9M$28.2M
20102010-12-31−$14.3M−$62.7M
20092009-12-31$48.4M

Sinovac Biotech operating cash flow trends

Over the last five fiscal years, Sinovac Biotech's operating cash flow decreased from $479.3M to −$512.2M, a change of −$991.5M.

About the metric

What operating cash flow means

Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.

Calculation and source

SEC-reported operating cash flow

TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Sinovac Biotech source filings ↗

Community posts

It’s quiet here.

No posts about SVA yet. Start the conversation.

Write the first post